RxDoctor Payments Data

Nathan Carberry, MD

Neuromuscular Medicine · Miami, FLNPI 1083147839

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $4,213 of the $4,883 with a category attached, or 86.3%. Biogen accounts for 86.8% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $4,453 and has fallen 99.4% since, to $25 in 2025.

$4,883in general payments, 2019–2025

Across 19 payments — averaging $256.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biogen$4K
  • EMD Serono, Inc.$271
  • AstraZeneca$141
  • Argenx US, Inc.$122
  • Biohaven Pharmaceutical Holding Company Ltd.$66
  • Teva Pharmaceuticals USA, Inc.$26
  • plus $19 from 1 others
$371,907in research payments, 2019–2025

Across 1 payment — averaging $371,907 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$372K

What the payments were for

  • Speaking & faculty fees$4,21386%
  • Food & beverage$67014%

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few neuromuscular medicine providers in Floridato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$48,608
Medicare patients
103
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Radicava OrsEdaravone31$409,385
Gamunex-CImmune Globul G/Gly/Iga Avg 4658$404,189
GammakedImmune Globul G/Gly/Iga Avg 4635$276,683
RelyvrioSod Phenylbutyrat/Taurursodiol18$232,677
PrivigenImmun Glob G(Igg)/Pro/Iga 0-5014$201,242
NuedextaDextromethorphan Hbr/Quinidine25$37,912
Riluzole42$5,962
Pyridostigmine Bromide16$1,948
Gabapentin78$1,758
Atropine Sulfate13$1,190
Glycopyrrolate17$955
Baclofen28$760
Duloxetine Hcl23$754
Pregabalin31$660
Prednisone22$208

Paid to pharmacies, not to this prescriber.

Other neuromuscular medicine in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →